drugset / Trial / NCT00308061

Summary

This study tested the safety of a new malaria vaccine in adults in Mali, West Africa, and measured the ability of the vaccine to stimulate antibodies directed against the malaria protein that the vaccine is based on. Forty adults were randomly assigned to get either the experimental malaria vaccine or a rabies vaccine, for comparison.

Timeline

Start
2003-07
Primary completion
2004-09
Completion
2005-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject FMP1 Protein / enzyme biologic 62.5 ug Intramuscular
Subject FMP1 Protein / enzyme biologic 0.5 ml Intramuscular
Comparator Imovax Rabies Vaccine Vaccine 1 ml Intramuscular

Indications